Non-profit drug research and development: the case study of Genethon
Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms...
Saved in:
Main Authors: | Szymon Jarosławski (Author), Mondher Toumi (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
by: Jarosławski Szymon, et al.
Published: (2011) -
Quantifying the persisting orphan-drug shortage public health crisis in the United States
by: Szymon Jarosławski, et al.
Published: (2017) -
Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018) -
Patient-reported outcome claims in European and United States orphan drug approvals
by: Szymon Jarosławski, et al.
Published: (2018) -
Health-related quality of life of patients after ischaemic stroke treated in a provincial hospital in Poland
by: Szymon Jarosławski, et al.
Published: (2020)